Scott Vandermeer
Founder at Infusion 51A LP
Profile
Scott Vandermeer is the founder of Infusion 51A LP, founded in 2015, where he holds the title of Managing Partner.
He was also the founder of Vivacitas Oncology, Inc., founded in 2015, where he held the title of Chief Financial Officer & Director.
Currently, he is the Chief Financial Officer at International Infusion LP since 2011.
In the past, he worked as the Chief Executive & Financial Officer at Theralink Technologies, Inc. (Colorado) from 2017 to 2020.
Mr. Vandermeer completed his undergraduate degree from the University of Illinois in 2008.
Scott Vandermeer active positions
Companies | Position | Start |
---|---|---|
Infusion 51A LP | Founder | 2015-03-31 |
International Infusion LP | Director of Finance/CFO | 2011-03-31 |
Vivacitas Oncology, Inc.
Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Founder | 2014-12-31 |
Former positions of Scott Vandermeer
Companies | Position | End |
---|---|---|
AVANT DIAGNOSTICS INC | Chief Executive Officer | - |
Training of Scott Vandermeer
University of Illinois | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Infusion 51A LP | Miscellaneous |
International Infusion LP | |
Vivacitas Oncology, Inc.
Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Health Services |
Theralink Technologies, Inc. (Colorado)
Theralink Technologies, Inc. (Colorado) Medical SpecialtiesHealth Technology Theralink Technologies, Inc. engages in the provision of biomarker assay services in the areas of oncology. The firm offers personalized medicine data through TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying drug treatments. It develops phosphoproteomic technologies that measure the activation status of signaling pathways. The company was founded on October 16, 2008 and is headquartered in Golden, CO. | Health Technology |
- Stock Market
- Insiders
- Scott Vandermeer